Ticker LaunchReverse merger · Completed · ONCT
Oncternal Therapeutics, Inc.
Reverse merger with GTx, Inc. (GTXI)
Oncternal Therapeutics, Inc. merged into GTx, Inc. (GTXI), a Nasdaq-listed biotech with a preclinical selective androgen receptor degrader (SARD) program, in a reverse merger that takes the private company public. The deal was announced on Mar 7, 2019 and closed on Jun 7, 2019. The combined company trades as Oncternal Therapeutics, Inc. (ONCT) on Nasdaq.
Oncternal Therapeutics is a clinical-stage biopharmaceutical company developing cancer therapies, led by cirmtuzumab, an anti-ROR1 monoclonal antibody studied with ibrutinib in CLL and MCL, and TK-216, a small-molecule inhibitor of ETS-family oncoproteins.
- Status
- Completed
- Private company
- Oncternal Therapeutics, Inc.
- Public company
- GTx, Inc. (GTXI)
- Public company business before
- Nasdaq-listed biotech with a preclinical selective androgen receptor degrader (SARD) program
- Announced
- Mar 7, 2019
- Closed
- Jun 7, 2019
- Combined company
- Oncternal Therapeutics, Inc. (ONCT)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Ownership split between private and public holders
- Contingent value rights (CVR)
- Reverse stock split
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
Other completed reverse mergers
- Bangtong Technology International Limitedinto Sunrise Tours, Inc. · Jun 21, 2019
- Edesa Biotech Inc.into Stellar Biotechnologies, Inc. · Jun 7, 2019
- Red Cat Propware, Inc.into TimefireVR Inc. · May 15, 2019
- C3J Therapeutics, Inc.into AmpliPhi Biosciences Corporation · May 10, 2019
- China VTV Ltd. (Hong Kong target)into China VTV Limited · May 8, 2019
- Adynxx, Inc.into Alliqua BioMedical, Inc. · May 3, 2019